J. Safra Sarasin Holding AG Acquires 7,543 Shares of Medtronic PLC $MDT

J. Safra Sarasin Holding AG boosted its holdings in Medtronic PLC (NYSE:MDT) by 24.1% during the 3rd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 38,856 shares of the medical technology company’s stock after buying an additional 7,543 shares during the period. J. Safra Sarasin Holding AG’s holdings in Medtronic were worth $3,694,000 as of its most recent SEC filing.

Other hedge funds also recently modified their holdings of the company. Norges Bank acquired a new position in Medtronic during the 2nd quarter valued at $1,432,698,000. Vanguard Group Inc. grew its position in Medtronic by 1.5% in the 2nd quarter. Vanguard Group Inc. now owns 126,909,406 shares of the medical technology company’s stock worth $11,062,693,000 after purchasing an additional 1,895,165 shares during the last quarter. Arrowstreet Capital Limited Partnership increased its holdings in shares of Medtronic by 332.0% during the 2nd quarter. Arrowstreet Capital Limited Partnership now owns 1,494,782 shares of the medical technology company’s stock worth $130,300,000 after purchasing an additional 1,148,803 shares during the period. Laurel Wealth Advisors LLC raised its position in shares of Medtronic by 8,779.8% during the second quarter. Laurel Wealth Advisors LLC now owns 1,069,664 shares of the medical technology company’s stock valued at $93,243,000 after buying an additional 1,057,618 shares during the last quarter. Finally, Altrinsic Global Advisors LLC lifted its stake in shares of Medtronic by 47.7% in the second quarter. Altrinsic Global Advisors LLC now owns 2,688,334 shares of the medical technology company’s stock valued at $234,342,000 after buying an additional 868,256 shares during the period. 82.06% of the stock is owned by institutional investors.

Analyst Upgrades and Downgrades

Several brokerages recently issued reports on MDT. Morgan Stanley boosted their price target on Medtronic from $107.00 to $117.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Weiss Ratings reissued a “buy (b-)” rating on shares of Medtronic in a report on Monday, December 29th. Wells Fargo & Company upped their target price on Medtronic from $100.00 to $114.00 and gave the company an “overweight” rating in a research note on Wednesday, November 19th. Jefferies Financial Group reaffirmed a “hold” rating and issued a $110.00 target price on shares of Medtronic in a research report on Wednesday, November 19th. Finally, TD Cowen reissued a “buy” rating on shares of Medtronic in a report on Friday, November 14th. Fourteen investment analysts have rated the stock with a Buy rating and eleven have assigned a Hold rating to the company. According to MarketBeat.com, Medtronic presently has an average rating of “Moderate Buy” and an average price target of $110.28.

Medtronic Stock Performance

NYSE MDT opened at $100.71 on Wednesday. The company has a 50 day moving average of $99.52 and a 200-day moving average of $95.48. Medtronic PLC has a 1-year low of $79.55 and a 1-year high of $106.33. The firm has a market cap of $129.12 billion, a price-to-earnings ratio of 27.15, a PEG ratio of 2.65 and a beta of 0.71. The company has a current ratio of 2.42, a quick ratio of 1.80 and a debt-to-equity ratio of 0.57.

Medtronic (NYSE:MDT) last announced its earnings results on Tuesday, November 18th. The medical technology company reported $1.36 earnings per share for the quarter, beating analysts’ consensus estimates of $1.31 by $0.05. The company had revenue of $8.96 billion during the quarter, compared to analyst estimates of $8.86 billion. Medtronic had a return on equity of 14.86% and a net margin of 13.71%.The firm’s quarterly revenue was up 6.6% compared to the same quarter last year. During the same period last year, the company posted $1.26 earnings per share. Medtronic has set its FY 2026 guidance at 5.620-5.660 EPS. On average, equities analysts forecast that Medtronic PLC will post 5.46 earnings per share for the current fiscal year.

Medtronic Announces Dividend

The business also recently declared a quarterly dividend, which was paid on Friday, January 16th. Stockholders of record on Friday, December 26th were paid a dividend of $0.71 per share. This represents a $2.84 annualized dividend and a dividend yield of 2.8%. The ex-dividend date of this dividend was Friday, December 26th. Medtronic’s dividend payout ratio is 76.55%.

Medtronic Profile

Medtronic plc is a global medical technology company that develops and manufactures a broad range of therapeutic devices and health care solutions. Headquartered legally in Ireland with principal operational offices in the United States, the company markets products to hospitals, physicians and health systems worldwide and has grown from its founding in 1949 into one of the largest medical-device manufacturers serving global health-care markets.

Medtronic’s offerings span several clinical areas, including cardiac rhythm and heart failure (pacemakers, implantable cardioverter‑defibrillators and related cardiac therapies), minimally invasive and surgical technologies (laparoscopic and advanced energy devices, visualization systems and surgical innovations), restorative therapies (spine and orthopedics, neuromodulation and neurovascular treatments) and diabetes management (insulin-delivery systems and glucose monitoring solutions).